1
NR566 Weeks 1–4 Midterm Due March 2026 (Advanced
Pharmacology for Care of the Family) + NR-509 (Advanced
Physical Assessment) Midterm Proctored Exam Questions and
Answers | 100% Pass Guaranteed | Graded A+ | |
Chamberlain University | 2025/2026 Academic Year
This resource presents the most tested and highest-difficulty exam questions from the NR566
Midterm and NR-509 Advanced Physical Assessment exams. Every core topic includes full
rotation variants — multiple alternate question formulations testing the same concept from
different clinical angles — so you can recognize the underlying principle regardless of how the
exam presents it. All answers include detailed expert-reviewed rationales.
SECTION A — NR566: ADVANCED PHARMACOLOGY FOR CARE OF THE FAMILY (Weeks 1–4)
Topic Cluster 1: Pharmacokinetics, Pharmacodynamics & Drug Absorption
Q1 (Core). Absorption is best defined as the:
A. Process by which the liver breaks down a drug into metabolites
B. Movement of drug from the administration site into the bloodstream
C. Distribution of drug to target tissues throughout the body
D. Elimination of drug through the kidneys
Correct Answer: B
Rationale: Absorption is the movement of a drug from its site of administration into the
systemic circulation. Oral drugs then undergo first-pass metabolism in the liver, which can
significantly reduce bioavailability.
Q1 – Rotation A (Bioavailability). Bioavailability is highest with which route of administration?
A. Oral
B. Intramuscular
C. Subcutaneous
D. Intravenous
pg. 1
,2
Correct Answer: D
Rationale: IV administration provides 100% bioavailability because the drug enters the
systemic circulation directly, bypassing absorption barriers and the first-pass effect.
Q1 – Rotation B (Volume of Distribution). A drug with a large volume of distribution (Vd > 1
L/kg) is most likely:
A. Highly protein-bound and confined to the vascular space
B. Water-soluble and excreted unchanged in urine
C. Lipid-soluble and distributed into fat, muscle, and organs
D. Subject to extensive first-pass metabolism
Correct Answer: C
Rationale: A large Vd indicates the drug distributes widely into tissues beyond the vascular
space. Lipid-soluble drugs (e.g., diazepam) penetrate fat, muscle, and organs. A small
Vd indicates the drug remains primarily plasma protein-bound (e.g., warfarin).
Q1 – Rotation C (Narrow Therapeutic Index). Which of the following medications requires
serum level monitoring due to a narrow therapeutic index?
A. Metformin
B. Digoxin
C. Lisinopril
D. Amoxicillin
Correct Answer: B
Rationale: Digoxin, lithium, and warfarin have narrow therapeutic indices — small changes in
dose or serum concentration can lead to subtherapeutic effects or toxicity. These drugs require
therapeutic drug monitoring.
Q1 – Rotation D (Agonist vs. Antagonist). Agonists produce:
A. Blockade of receptor activation
B. A maximal response when the receptor is occupied
C. No response regardless of receptor binding
D. A response only when combined with antagonists
Correct Answer: B
Rationale: Agonists bind to receptors and produce a maximal response when the receptor is
occupied. Antagonists block receptor activation; partial agonists have lower efficacy even at full
receptor occupancy.
Topic Cluster 2: Lipid Management & ASCVD Prevention
Q2 (Core). A 65-year-old woman presents for a follow-up examination. She is a smoker, and her
hypertension is now adequately controlled with medication. Her mother died at age 40 from a
heart attack. The fasting lipid profile shows cholesterol = 240 mg/dL, HDL = 30, and LDL = 180.
In addition to starting therapeutic lifestyle changes, the nurse practitioner should start the
pg. 2
,3
patient on:
A. A bile acid sequestrant
B. A cholesterol absorption inhibitor
C. A statin
D. Niacin
Correct Answer: C
Rationale: Statin therapy represents the most aggressive and effective option for LDL reduction
in patients with multiple cardiovascular risk factors (active smoker, hypertension, premature
coronary disease history, significantly elevated LDL). Statins are first-line lipid-lowering therapy
for ASCVD prevention.
Q2 – Rotation A (Statin Adverse Effect). A patient on atorvastatin 40 mg daily reports new-
onset diffuse muscle pain and dark urine. The nurse practitioner should first:
A. Reassure the patient that muscle aches are expected with statins
B. Order a serum creatine kinase (CK) level and discontinue the statin
C. Reduce the statin dose by half
D. Add coenzyme Q10 supplementation
Correct Answer: B
Rationale: Muscle pain with dark urine suggests rhabdomyolysis, a rare but life-threatening
adverse effect of statins. Immediate CK measurement and statin discontinuation are warranted.
Statin-induced myopathy requires prompt recognition to prevent acute kidney injury from
myoglobinuria.
Q2 – Rotation B (Statin + Grapefruit). A patient taking atorvastatin should be counseled to
avoid:
A. Dairy products
B. Grapefruit and grapefruit juice
C. Green leafy vegetables
D. Whole grains
Correct Answer: B
Rationale: Grapefruit inhibits CYP3A4, the primary hepatic enzyme that metabolizes
atorvastatin, simvastatin, and lovastatin. Concurrent grapefruit consumption significantly
increases statin serum concentrations and the risk of myopathy and rhabdomyolysis.
Q2 – Rotation C (Statin Monitoring). Which laboratory test should be monitored at baseline
and periodically in patients on statin therapy?
A. Serum creatinine
B. Complete blood count
C. Liver function tests (ALT/AST)
D. Thyroid stimulating hormone
pg. 3
, 4
Correct Answer: C
Rationale: Statins can cause hepatotoxicity manifested by elevated transaminases. Baseline
LFTs should be obtained prior to initiating therapy and monitored periodically. Statins are
contraindicated in active liver disease.
Q2 – Rotation D (Non-Statin Therapy). A patient with ASCVD has persistent LDL elevation
despite maximally tolerated statin therapy. Which agent should be added next?
A. Niacin
B. Ezetimibe
C. Fenofibrate
D. Omega-3 fatty acids
Correct Answer: B
Rationale: Ezetimibe (a cholesterol absorption inhibitor) is the preferred add-on to statin
therapy based on the IMPROVE-IT trial, which demonstrated incremental ASCVD risk reduction
when ezetimibe was added to statin therapy. PCSK9 inhibitors are reserved for very high-risk
patients who do not achieve adequate LDL lowering on statin plus ezetimibe.
Topic Cluster 3: Hypertension & Cardiovascular Pharmacology
Q3 (Core). Which of the following end-organ sequelae is NOT directly caused by uncontrolled
hypertension?
A. Proteinuria
B. AV nicking
C. Hemorrhagic stroke
D. Peripheral neuropathy
Correct Answer: D
Rationale: Although patients with hypertension frequently have peripheral neuropathy, it is
only directly attributed to patients who are also diabetic and is commonly found in non-
hypertensive diabetic patients. Proteinuria, AV nicking, and hemorrhagic stroke are all directly
caused by uncontrolled hypertension.
Q3 – Rotation A (HFrEF Medication). Which of the following blood pressure medications is NOT
recommended for heart failure with reduced ejection fraction (HFrEF)?
A. Carvedilol
B. Amlodipine
C. Lisinopril
D. Spironolactone
Correct Answer: B
Rationale: Guideline-directed medical therapy for HFrEF includes beta-blockers (carvedilol,
metoprolol succinate, bisoprolol), ACE inhibitors/ARBs/ARNI (lisinopril, sacubitril/valsartan),
and mineralocorticoid receptor antagonists (spironolactone, eplerenone). Amlodipine, a
pg. 4
NR566 Weeks 1–4 Midterm Due March 2026 (Advanced
Pharmacology for Care of the Family) + NR-509 (Advanced
Physical Assessment) Midterm Proctored Exam Questions and
Answers | 100% Pass Guaranteed | Graded A+ | |
Chamberlain University | 2025/2026 Academic Year
This resource presents the most tested and highest-difficulty exam questions from the NR566
Midterm and NR-509 Advanced Physical Assessment exams. Every core topic includes full
rotation variants — multiple alternate question formulations testing the same concept from
different clinical angles — so you can recognize the underlying principle regardless of how the
exam presents it. All answers include detailed expert-reviewed rationales.
SECTION A — NR566: ADVANCED PHARMACOLOGY FOR CARE OF THE FAMILY (Weeks 1–4)
Topic Cluster 1: Pharmacokinetics, Pharmacodynamics & Drug Absorption
Q1 (Core). Absorption is best defined as the:
A. Process by which the liver breaks down a drug into metabolites
B. Movement of drug from the administration site into the bloodstream
C. Distribution of drug to target tissues throughout the body
D. Elimination of drug through the kidneys
Correct Answer: B
Rationale: Absorption is the movement of a drug from its site of administration into the
systemic circulation. Oral drugs then undergo first-pass metabolism in the liver, which can
significantly reduce bioavailability.
Q1 – Rotation A (Bioavailability). Bioavailability is highest with which route of administration?
A. Oral
B. Intramuscular
C. Subcutaneous
D. Intravenous
pg. 1
,2
Correct Answer: D
Rationale: IV administration provides 100% bioavailability because the drug enters the
systemic circulation directly, bypassing absorption barriers and the first-pass effect.
Q1 – Rotation B (Volume of Distribution). A drug with a large volume of distribution (Vd > 1
L/kg) is most likely:
A. Highly protein-bound and confined to the vascular space
B. Water-soluble and excreted unchanged in urine
C. Lipid-soluble and distributed into fat, muscle, and organs
D. Subject to extensive first-pass metabolism
Correct Answer: C
Rationale: A large Vd indicates the drug distributes widely into tissues beyond the vascular
space. Lipid-soluble drugs (e.g., diazepam) penetrate fat, muscle, and organs. A small
Vd indicates the drug remains primarily plasma protein-bound (e.g., warfarin).
Q1 – Rotation C (Narrow Therapeutic Index). Which of the following medications requires
serum level monitoring due to a narrow therapeutic index?
A. Metformin
B. Digoxin
C. Lisinopril
D. Amoxicillin
Correct Answer: B
Rationale: Digoxin, lithium, and warfarin have narrow therapeutic indices — small changes in
dose or serum concentration can lead to subtherapeutic effects or toxicity. These drugs require
therapeutic drug monitoring.
Q1 – Rotation D (Agonist vs. Antagonist). Agonists produce:
A. Blockade of receptor activation
B. A maximal response when the receptor is occupied
C. No response regardless of receptor binding
D. A response only when combined with antagonists
Correct Answer: B
Rationale: Agonists bind to receptors and produce a maximal response when the receptor is
occupied. Antagonists block receptor activation; partial agonists have lower efficacy even at full
receptor occupancy.
Topic Cluster 2: Lipid Management & ASCVD Prevention
Q2 (Core). A 65-year-old woman presents for a follow-up examination. She is a smoker, and her
hypertension is now adequately controlled with medication. Her mother died at age 40 from a
heart attack. The fasting lipid profile shows cholesterol = 240 mg/dL, HDL = 30, and LDL = 180.
In addition to starting therapeutic lifestyle changes, the nurse practitioner should start the
pg. 2
,3
patient on:
A. A bile acid sequestrant
B. A cholesterol absorption inhibitor
C. A statin
D. Niacin
Correct Answer: C
Rationale: Statin therapy represents the most aggressive and effective option for LDL reduction
in patients with multiple cardiovascular risk factors (active smoker, hypertension, premature
coronary disease history, significantly elevated LDL). Statins are first-line lipid-lowering therapy
for ASCVD prevention.
Q2 – Rotation A (Statin Adverse Effect). A patient on atorvastatin 40 mg daily reports new-
onset diffuse muscle pain and dark urine. The nurse practitioner should first:
A. Reassure the patient that muscle aches are expected with statins
B. Order a serum creatine kinase (CK) level and discontinue the statin
C. Reduce the statin dose by half
D. Add coenzyme Q10 supplementation
Correct Answer: B
Rationale: Muscle pain with dark urine suggests rhabdomyolysis, a rare but life-threatening
adverse effect of statins. Immediate CK measurement and statin discontinuation are warranted.
Statin-induced myopathy requires prompt recognition to prevent acute kidney injury from
myoglobinuria.
Q2 – Rotation B (Statin + Grapefruit). A patient taking atorvastatin should be counseled to
avoid:
A. Dairy products
B. Grapefruit and grapefruit juice
C. Green leafy vegetables
D. Whole grains
Correct Answer: B
Rationale: Grapefruit inhibits CYP3A4, the primary hepatic enzyme that metabolizes
atorvastatin, simvastatin, and lovastatin. Concurrent grapefruit consumption significantly
increases statin serum concentrations and the risk of myopathy and rhabdomyolysis.
Q2 – Rotation C (Statin Monitoring). Which laboratory test should be monitored at baseline
and periodically in patients on statin therapy?
A. Serum creatinine
B. Complete blood count
C. Liver function tests (ALT/AST)
D. Thyroid stimulating hormone
pg. 3
, 4
Correct Answer: C
Rationale: Statins can cause hepatotoxicity manifested by elevated transaminases. Baseline
LFTs should be obtained prior to initiating therapy and monitored periodically. Statins are
contraindicated in active liver disease.
Q2 – Rotation D (Non-Statin Therapy). A patient with ASCVD has persistent LDL elevation
despite maximally tolerated statin therapy. Which agent should be added next?
A. Niacin
B. Ezetimibe
C. Fenofibrate
D. Omega-3 fatty acids
Correct Answer: B
Rationale: Ezetimibe (a cholesterol absorption inhibitor) is the preferred add-on to statin
therapy based on the IMPROVE-IT trial, which demonstrated incremental ASCVD risk reduction
when ezetimibe was added to statin therapy. PCSK9 inhibitors are reserved for very high-risk
patients who do not achieve adequate LDL lowering on statin plus ezetimibe.
Topic Cluster 3: Hypertension & Cardiovascular Pharmacology
Q3 (Core). Which of the following end-organ sequelae is NOT directly caused by uncontrolled
hypertension?
A. Proteinuria
B. AV nicking
C. Hemorrhagic stroke
D. Peripheral neuropathy
Correct Answer: D
Rationale: Although patients with hypertension frequently have peripheral neuropathy, it is
only directly attributed to patients who are also diabetic and is commonly found in non-
hypertensive diabetic patients. Proteinuria, AV nicking, and hemorrhagic stroke are all directly
caused by uncontrolled hypertension.
Q3 – Rotation A (HFrEF Medication). Which of the following blood pressure medications is NOT
recommended for heart failure with reduced ejection fraction (HFrEF)?
A. Carvedilol
B. Amlodipine
C. Lisinopril
D. Spironolactone
Correct Answer: B
Rationale: Guideline-directed medical therapy for HFrEF includes beta-blockers (carvedilol,
metoprolol succinate, bisoprolol), ACE inhibitors/ARBs/ARNI (lisinopril, sacubitril/valsartan),
and mineralocorticoid receptor antagonists (spironolactone, eplerenone). Amlodipine, a
pg. 4
